48 lower than these perfused with BAY 412272 alone (11.15 0.91 vs. 17.76 1.87 fmol/mg tissue, P , 0.05). Similarly, cGMP levels in LV tissue perfused with each CPTIO and BAY 412272 were 54 lower than BAY 412272 alone (8.29 0.52 vs. 17.76 1.87 fmol/mg tissue, P , 0.001) (Figure 3B).three.three Cardioprotective effects of sGC activator BAY 60In Series three, we investigated the infarctlimiting properties of sGC activation of BAY 602770 which targets the oxidized Fe3 and haemfree forms of the protein. three.three.1 Infarct size Baseline haemodynamic parameters and area at risk for all groups in this series were comparable among groups (Table 1). The sGC activator BAY 602770 afforded protection across the concentration range five nM mM during early reperfusion from 33.0 2.six in handle hearts to 22.0 2.8 (P , 0.01) for hearts treated using the highest concentration. Even so, no concentration effect was observed (Figure 4A). To confirm the haem independence of BAY 602770’s action additional hearts have been coperfused with two mM ODQ. Concomitant perfusion of ODQ with all the lowest concentration of BAY 602770 (5 nM) limited3.two Cardioprotective effects of exogenous NOIn Series two, we explored the effects of exogenously administered NO, in the donor compound NOC9, on limiting infarct size when administered throughout early reperfusion.sGC and reperfusion injuryTable 1 Baseline cardiodynamic information for infarct experiments in series 1, 2, andSeries Remedy group (quantity) n CFR (mL/min) HR (BPM) LVDP (mmHg) RPP (mmHg/ min three 103) Vol. LV and RV (cm3) Risk zone vol. (cm3) Risk zone ( vol. LV and RV)…………………………………………………………………………………………………………………………………………………………………1 Control (1) BAY 41 100 nM (2) BAY 41 300 nM (3) BAY 41 1 mM (4) BAY 41 3 mM (5) ODQ 2 mM BAY 41 three mM (six) ODQ two mM (7) LNAME one hundred mM BAY 41 3 mM (eight) LNAME 100 mM (9) CPTIO 30 mM BAY 41 3 mM (ten) CPTIO 30 mM (11) Manage (12) NOC9 1 nM (13) NOC9 10 nM (14) NOC9 100 nM (15) NOC9 1 mM (16) Manage (17) BAY 60 5 nM (18) BAY 60 50 nM (19) BAY 60 500 nM (20) BAY 60 1 mM (21) ODQ 2 mM (22) BAY 60 5 nM ODQ two mM (23) BAY 60 five nM CPTIO 30 mM (24) CPTIO 30 mM (25) BAY 41 1 mM (26) BAY 60 five nM BAY 41 1 mM (27) 17 7 six six 7 7 6 eight 6 6 6 12 6 six six 9 18 six eight eight 7 six 7 6 six 6 six 14.1622843-37-1 uses 6 1.5-Bromobenzo[b]thiophene-3-carbaldehyde Chemscene 0 17.3 1.0 15.3 0.7 18.1 1.three 17.1 1.2 15.7 0.8 14.7 1.two 15.3 0.6 13.eight 0.7 16.8 0.7 15.7 0.7 14.6 0.six 14.9 1.1 15.2 0.eight 14.4 0.two 15.9 0.8 16.PMID:24202965 8 0.six 17.3 1.0 16.1 1.0 14.six 0.6 16.five 1.1 16.9 0.9 15.five 1.0 14.1 0.7 14.7 0.8 14.1 0.six 15.two 1.six 272 8 296 12 295 ten 293 11 296 18 311 ten 315 21 290 9 309 17 298 6 313 six 313 ten 327 11 322 8 329 14 341 four 315 six 319 15 331 five 322 7 336 four 316 7 310 7 333 four 320 6 313 9 323 9 69.three 4.3 62.7 4.6 59.7 three.9 69.two four.five 69.7 four.7 80.0 eight.7 70.7 10.five 68.four six.three 61.2 1.8 63.1 three.six 64.5 four.8 66.0 six.6 69.9 four.8 70.1 six.1 63.9 eight.7 69.0 four.9 65.9 3.1 69.0 5.0 68.1 4.0 68.7 three.7 69.six 4.8 61.9 1.7 69.five four.eight 73.9 6.six 67.4 7.five 69.5 4.four 68.six 5.three 18.9 1.4 18.7 1.7 17.6 1.1 20.three 1.five 21.0 two.6 24.four two.0 21.7 two.three 19.five 1.three 18.three 1.0 18.8 1.0 20.2 1.5 20.4 1.7 22.four 1.four 21.9 1.2 20.five 1.9 22.9 1.8 20.7 0.9 22.1 two.0 22.five 1.4 22.1 1.3 23.4 1.4 19.6 0.7 21.five 1.7 24.7 two.three 21.five 2.four 21.6 0.9 22.1 1.eight 0.95 0.03 0.87 0.03 0.87 0.05 0.91 0.04 0.95 0.03 1.01 0.04 0.98 0.02 0.96 0.05 0.89 0.27 1.07 0.03 1.03 0.05 0.81 0.04 0.81 0.06 0.83 0.0.